Author

Yike Lin

Observed name: Y. Lin

Institution: Xiangnan University

Observed institutions: Eli Lilly (United States), First Affiliated Hospital of Guangzhou Medical University, First Affiliated Hospital of Shantou University Medical College, Xiangnan University

ORCID: 0009-0004-7258-6060

Observed ORCID: 0009-0004-7258-6060

OpenAlex ID: A5101081084

2229P Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001

2023 · L.J. Wirth, V. Subbiah, et al. · Annals of Oncology · 6

1846MO Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases

2025 · P. Cassier, J. Schneider, et al. · Annals of Oncology · 4

Identification of a Novel Three-immunogene Diagnostic Signature for Alopecia Areata

2024 · Xiuwen Chen, Wenzi Liang, et al. · Annals of Dermatology · 1

Zhuche Pill alleviates DSS-induced colonic epithelial injury in mice: involvement of IL-17/NF-κB and Wnt/β-catenin signaling pathways

2026 · Tao Zhang, Beiyang Cong, et al. · Journal of Ethnopharmacology

1275P Genomic analysis of lung adenocarcinoma with micropapillary component: Identification of micropapillary-related subtypes and development of a prognostic model

2023 · Y. Lin, Y. Jiang, et al. · Annals of Oncology

Clinical Application Of Oral Meglumine Diatrizoate Esophagogram Inscreening For Esophageal Fistula During Radiotherapy For Esophageal Cancer

2020 · L. Geng, R. Wu, et al. · International Journal of Radiation Oncology*Biology*Physics

Works count: 6

Citation count: 11

H-index: 2

I10-index: